Preferred Label : Dimopoulos Waldenstroms Macroglobulinemia 2018 Oncology Response Criteria;
NCIt related terms : DIMOPOULOS WALDENSTROMS MACROGLOBULINEMIA 2018;
Alternative definition : CDISC: Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia.
(Dimopoulos MA, Tedeschi A, Trotman J, Garcia Sanz R, Macdonald D, Leblond V, Mahe
B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon
SP, Li J, Salman Z, Graef T, Buske C. Phase 3 Trial of Ibrutinib plus Rituximab in
Waldenstrom's Macroglobulinemia for the iNNOVATE Study Group and the European Consortium
for Waldenstrom's Macroglobulinemia. N Engl J Med 2018;378:2399-410.);
NCI Metathesaurus CUI : CL1647627;
Origin ID : C178056;
UMLS CUI : C5554817;
Semantic type(s)
- concept_is_in_subset
